- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02363244
Pap and HPVDNA Before and After Acetic Acid
A Pilot Study on Comparative Evaluation of Results of Pap Smears and HPV Hybrid Capture 2 Performed on Cervical Samples Before and After Application of Acetic Acid
Study Overview
Status
Conditions
Detailed Description
Aim (of pilot study):
To evaluate the cell adequacy and smear quality of Pap smears and adequacy of samples for HPV HC 2 collected before and after application of acetic acid.
Objective of Pilot study-
- Agreement between the results of HC2 on cervical samples obtained from women before and 5 to 10 mins after VIA test
- Correlation between RLU/ cutoff ratio of HC2 on cervical samples obtained from women before and 5 to 10 mins after VIA test.
- Agreement between the results of cytology on cervical smears obtained immediately before and 5 to 10 mins after VIA test from the same women.
Methodology:
Design: Pilot study
Study Duration: Three months
Study Site: Preventive Oncology screening clinic, Tata Memorial Hospital
Sample Size calculation and power estimates:
For the pilot study, sampling method is a convenience sample of 50 consecutive eligible women attending the Preventive Oncology screening clinic and consenting to participate in the study. These women will be randomly allocated using lottery method (wherein 25 chits with HPV and 25 chits with cytology written inside will be placed). For every participant woman a chit will be picked up and the woman will be allotted to either HPV or cytology testing depending on the message in the chit. Thereafter the chit will be discarded.
In 25 samples Pap smears will be collected before and after application of acetic acid. Steps mentioned below.
In rest 25 samples HPV DNA will be collected before and after application of acetic acid. Steps mentioned below.
Step 1: A per speculum examination will be performed on eligible women attending the Preventive Oncology screening clinic and the findings of the same will be recorded.
Step 2: Pap smear will be collected - Smear 1. OR Cervical cell samples will be collected for HPV HC II - HPV sample 1. Step 3: VIA will be performed and the findings will be noted. Step 4: A second Pap smear will be collected 5 to 10 minutes after performing VIA when the woman is still on the examination table by the same provider- Smear 2.
OR Cervical cell samples will be collected for HPV HC II - HPV sample 2. Step 5: The smears will be submitted to the cytology department for evaluation. The HPV HC II samples will be submitted to the Microbiology department for evaluation.
Step 6: The cytologist reading the smear will be blinded as to which smear was taken before and which was taken after the application of acetic acid. The same cytologist will read the pre-VIA and the post-VIA smears.
Similarly, the Microbiology department staff will be blinded as to which HPV sample was taken before and which was taken after the application of acetic acid. The paired samples will be analyzed at the same laboratory in the same batch of testing.
Step 7: The screen negative women will undergo routine follow-up. The screen positive women will undergo Colposcopy, guided biopsy and further management according to the Tata Memorial Hospital protocol.
Analysis of the variables Data entry will be done in the Department of Preventive Oncology, Tata Memorial Hospital using SPSS version 18. Checks for consistency, data safety and analysis will be carried out at regular intervals. Both descriptive and inferential statistics will be generated for describing variables under the study objectives. Agreement in HC2 results between pre-VIA and post-VIA samples will be estimated using kappa statistics. Similarly, agreement in pap results between pre-VIA and post-VIA samples will be estimated using kappa statistics. Sensitivity and specificity of HC2 test and pap test in detecting CIN2+ lesions will be calculated using negative colposcopy or biopsy as the gold standard and will be compared between the pre and post VIA samples.
Study Type
Enrollment (Actual)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Married women attending the Preventive Oncology screening clinic.
- women in age group 30 to 60 years
Exclusion Criteria
- Unmarried women
- married women in the age group less than 30 years and above 60 years
- pregnant women
- women with history of total hysterectomy
- women with cervical cancer
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Pap group
Per speculum examination will be done.Pap test will be collected for the women as per allotement.A via (visual inspection with acedic acid)test will be done.A repeat cervical cell for pap test will be collected and send to laboratory for further evaluation.
|
HPVDNA GROUP
Per speculum examination will be done.HPVDNA test will be collected for the women as per allotement.A via (visual inspection with acedic acid)test will be done.A repeat cervical cell for HPVDNA will be collected and send to laboratory for further evaluation.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Comparative Evaluation Of Results Of Pap Smears And HPV Hybrid Capture 2 Performed On Cervical Samples Before And After Application Of Acetic Acid.
Time Frame: 3 months
|
The purpose of this pilot study is to assess the cell adequacy and quality of Pap smears and adequacy of samples for HPV DNA virus test done after application of acetic acid.
|
3 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Gauravi A Mishra,, MD, Tata Memorial Centre
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 1413 Pap HPV Project
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on CIN
-
Bracco Diagnostics, IncCompleted
-
University of California, Los AngelesNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedHuman Papillomavirus | CIN 3 | CIN 2United States
-
Kaiyang LinCompleted
-
Osprey Medical, IncCompletedContrast Induced Nephropathy (CIN)United States, New Zealand, Australia
-
Medical University of GrazAbbott Diagnostics DivisionCompletedContrast Media Induced Nephropathy (CIN)Austria
-
Copenhagen University Hospital at HerlevCompletedRenal Adverse Events - Contrast Induced Nephropathy (CIN) | Non-renal Adverse EventsDenmark
-
University of CopenhagenAalborg University Hospital; Naestved Hospital; Hospital of South West Jutland; Randers Regional Hospital and other collaboratorsActive, not recruitingCervical Intraepithelial Neoplasia (CIN)Denmark
-
National Taiwan University HospitalUnknownPatient With Invasive Cervical Carcinoma | Patient With CIN Lesion | Patient With HPV Infected Patients Without Histopathologic Lesion | Normal Populations.Taiwan
-
National Cancer Institute (NCI)CompletedCervical Cancer | CIN | Neoplasia | Cervical IntraepithelialUnited States